CN103316016B - 一种含有卡马西平的药物组合物及其应用 - Google Patents
一种含有卡马西平的药物组合物及其应用 Download PDFInfo
- Publication number
- CN103316016B CN103316016B CN201310295165.1A CN201310295165A CN103316016B CN 103316016 B CN103316016 B CN 103316016B CN 201310295165 A CN201310295165 A CN 201310295165A CN 103316016 B CN103316016 B CN 103316016B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- carbamazepine
- epilepsy
- group
- aretigenin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 229960000623 carbamazepine Drugs 0.000 title claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 33
- 206010015037 epilepsy Diseases 0.000 claims abstract description 40
- 239000003814 drug Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 17
- 238000011534 incubation Methods 0.000 abstract description 11
- 206010010904 Convulsion Diseases 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 2
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 abstract 1
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 abstract 1
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 abstract 1
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 abstract 1
- 230000000204 effect on epilepsy Effects 0.000 abstract 1
- 208000028329 epileptic seizure Diseases 0.000 abstract 1
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 11
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 10
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 9
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 210000001320 hippocampus Anatomy 0.000 description 7
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 5
- 230000001037 epileptic effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 230000003556 anti-epileptic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000017194 Affective disease Diseases 0.000 description 1
- 206010052346 Brain contusion Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010053942 Cerebral haematoma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010021925 Inferiority complex Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 206010040703 Simple partial seizures Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000009516 brain contusion Effects 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000015754 perinatal disease Diseases 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
分组 | 样本量(只) | 剂量 |
正常对照组 | 12 | 0.4ml纯化水 |
模型对照组 | 12 | 0.4ml纯化水 |
卡马西平组 | 12 | 90mg·kg-1·d-1卡马西平 |
牛蒡苷元组 | 12 | 4.5mg·kg-1·d-1牛蒡苷元 |
复方低剂量组 | 12 | 45mg·kg-1·d-1卡马西平 + 2.3mg·kg-1·d-1牛蒡苷元 |
复方高剂量组 | 12 | 90mg·kg-1·d-1卡马西平 + 4.5mg·kg-1·d-1牛蒡苷元 |
分组 | 样本量(只) | 给药前潜伏期 | 给药后潜伏期 |
模型对照组 | 12 | 78.2±15.0 | 76.9±16.8 |
卡马西平组 | 12 | 80.8±17.9 | 163.3±24.7★★ |
牛蒡苷元组 | 12 | 79.5±15.6 | 88.6±28.5 |
复方低剂量组 | 12 | 78.8±19.1 | 177.0±21.6★★ |
复方高剂量组 | 12 | 81.0±18.4 | 206.2±23.4★★●▼▼ |
分组 | 样本量(只) | NOS(U/mg蛋白) | NO(μmol/g蛋白) |
正常对照组 | 12 | 0.851±0.042 | 2.158±0.247 |
模型对照组 | 12 | 1.913±0.164 | 5.814±0.710 |
卡马西平组 | 12 | 0.978±0.069★★ | 2.644±0.422★★ |
牛蒡苷元组 | 12 | 1.797±0.088 | 5.220±0.649 |
复方低剂量组 | 12 | 0.871±0.076★★▼▼ | 1.908±0.317★★●●▼▼ |
复方高剂量组 | 12 | 0.406±0.080★★●●▼▼ | 1.375±0.183★★●●▼▼ |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310295165.1A CN103316016B (zh) | 2013-07-15 | 2013-07-15 | 一种含有卡马西平的药物组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310295165.1A CN103316016B (zh) | 2013-07-15 | 2013-07-15 | 一种含有卡马西平的药物组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103316016A CN103316016A (zh) | 2013-09-25 |
CN103316016B true CN103316016B (zh) | 2014-08-13 |
Family
ID=49185250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310295165.1A Expired - Fee Related CN103316016B (zh) | 2013-07-15 | 2013-07-15 | 一种含有卡马西平的药物组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103316016B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109200053A (zh) * | 2018-11-17 | 2019-01-15 | 王海玲 | 一种抗癫痫外用药物及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1265889A (zh) * | 1999-03-06 | 2000-09-13 | 王学勇 | 一种治疗癫痫病的药物 |
CN101748169A (zh) * | 2010-01-12 | 2010-06-23 | 南京泽朗医药科技有限公司 | 一种从牛蒡子中制备牛蒡子苷元的方法 |
CN102240283A (zh) * | 2011-05-06 | 2011-11-16 | 南京泽朗农业发展有限公司 | 牛蒡子苷元在制备治疗过敏性哮喘药物中的应用 |
-
2013
- 2013-07-15 CN CN201310295165.1A patent/CN103316016B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1265889A (zh) * | 1999-03-06 | 2000-09-13 | 王学勇 | 一种治疗癫痫病的药物 |
CN101748169A (zh) * | 2010-01-12 | 2010-06-23 | 南京泽朗医药科技有限公司 | 一种从牛蒡子中制备牛蒡子苷元的方法 |
CN102240283A (zh) * | 2011-05-06 | 2011-11-16 | 南京泽朗农业发展有限公司 | 牛蒡子苷元在制备治疗过敏性哮喘药物中的应用 |
Non-Patent Citations (4)
Title |
---|
抗癫痫药卡马西平疗效与血药浓度的相关性研究;郭桂梅 等;《中风与神经疾病杂志》;20110430;第28卷(第4期);第336-337页 * |
牛蒡子苷及牛蒡子苷元的药理作用研究进展;王潞 等;《中草药》;20080331;第39卷(第3期);第467-470页 * |
王潞 等.牛蒡子苷及牛蒡子苷元的药理作用研究进展.《中草药》.2008,第39卷(第3期),第467-470页. |
郭桂梅 等.抗癫痫药卡马西平疗效与血药浓度的相关性研究.《中风与神经疾病杂志》.2011,第28卷(第4期),第336-337页. |
Also Published As
Publication number | Publication date |
---|---|
CN103316016A (zh) | 2013-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Verhoog et al. | Astrocytes as guardians of neuronal excitability: mechanisms underlying epileptogenesis | |
Cardinali | Melatonin: clinical perspectives in neurodegeneration | |
Ziemann et al. | TMS and drugs revisited 2014 | |
Raucci et al. | Cannabidiol treatment for refractory epilepsies in pediatrics | |
Maria Rossini et al. | Clinical neurophysiology of brain plasticity in aging brain | |
Shao et al. | Protective effects of thymoquinone against convulsant activity induced by lithium-pilocarpine in a model of status epilepticus | |
JP2005502680A (ja) | 抗痙攣剤およびアセチルコリンエステラーゼ阻害剤による痴呆および記憶障害の処置 | |
Chen et al. | Preoperative and postoperative analgesic techniques in the treatment of patients undergoing transabdominal hysterectomy: a preliminary randomized trial | |
Shao et al. | Gastrodin reduces the severity of status epilepticus in the rat pilocarpine model of temporal lobe epilepsy by inhibiting Nav1. 6 sodium currents | |
AU2018307730B9 (en) | Mesembrenol and/or mesembranol for prophylaxis and treatment of patients suffering from epilepsy and associated diseases | |
JP2022540253A (ja) | T型カルシウムチャネル調節因子の製剤およびその使用方法 | |
Simeon et al. | d-Cycloserine therapy of psychosis by symptom provocation | |
Ansari et al. | Gabapentin: a novel drug as add-on therapy in cases of refractory overactive bladder in children | |
RU2013127420A (ru) | Способы уменьшения психогенного или компульсивного переедания | |
Jiang et al. | Lithium affects rat hippocampal electrophysiology and epileptic seizures in a dose dependent manner | |
CN103316016B (zh) | 一种含有卡马西平的药物组合物及其应用 | |
Freeman | The treatment of neuropathic pain | |
Philbert et al. | The CRF1 receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: comparison with paroxetine and d-cycloserine | |
Vitet et al. | Beneficial effects of Gelsemium-based treatment against paclitaxel-induced painful symptoms | |
Leitão et al. | Benzodiazepine partially reverses tonic-clonic seizures induced by thiocolchicoside | |
C. Sekhar et al. | Protection by Nano-Encapsulated Bacoside A and Bacopaside I in Seizure Alleviation and Improvement in Sleep-In Vitro and In Vivo Evidences | |
Zhou et al. | Diazepam monotherapy or diazepam-ketamine dual therapy at different time points terminates seizures and reduces mortality in a status epilepticus animal model | |
Hübers et al. | Acute effects of lithium on excitability of human motor cortex | |
CN113041240B (zh) | Act001在制备治疗帕金森药物和治疗nlrp3炎症小体介导的神经炎药物上的应用 | |
CN108653739A (zh) | 可降低Gabapentinoid致肥胖副作用的镇痛抗癫痫组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170720 Address after: 510640 Guangdong City, Tianhe District Province, No. five, road, public education building, unit 371-1, unit 2401 Patentee after: Guangdong Gaohang Intellectual Property Operation Co., Ltd. Address before: 235000 Anhui Province Economic Development Zone Huaibei City Duji District Tengfei Road No. 7 Patentee before: Yu Fazhou |
|
TR01 | Transfer of patent right | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhao Haina Inventor before: Yu Fazhou |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170913 Address after: Si Zhen Jia Zhuang Cun, Zhenping county, Nanyang City, the 474250 stone Buddha in Henan province No. 999 Patentee after: Zhao Haina Address before: 510640 Guangdong City, Tianhe District Province, No. five, road, public education building, unit 371-1, unit 2401 Patentee before: Guangdong Gaohang Intellectual Property Operation Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140813 Termination date: 20180715 |